CA2242579A1 - Antagonistes benzimidazolyles du recepteur du neuropeptide y - Google Patents

Antagonistes benzimidazolyles du recepteur du neuropeptide y Download PDF

Info

Publication number
CA2242579A1
CA2242579A1 CA002242579A CA2242579A CA2242579A1 CA 2242579 A1 CA2242579 A1 CA 2242579A1 CA 002242579 A CA002242579 A CA 002242579A CA 2242579 A CA2242579 A CA 2242579A CA 2242579 A1 CA2242579 A1 CA 2242579A1
Authority
CA
Canada
Prior art keywords
alkylenyl
alkoxy
heterocyclic
phenyl
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002242579A
Other languages
English (en)
Inventor
Macklin Brian Arnold
Thomas Charles Britton
Robert Frederick Junior Bruns
Buddy Eugene Cantrell
Anne Marie Nunes
Philip Arthur Hipskind
James Jeffry Howbert
Karen Lynn Lobb
James Arthur Nixon
Paul Leslie Ornstein
Edward C. R. Smith
Hamideh Zarrinmayeh
Dennis Michael Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9600344.7A external-priority patent/GB9600344D0/en
Application filed by Individual filed Critical Individual
Publication of CA2242579A1 publication Critical patent/CA2242579A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une série de benzimidazoles substitués qui sont utiles dans le traitement ou la prévention d'un état associé à un excès de neuropeptides Y. L'invention concerne également des procédés mettant en application ces benzimidazoles substitués, ainsi que des formulations pharmaceutiques comprenant un ou plusieurs de ces composés en tant que principe actif.
CA002242579A 1996-01-09 1997-01-09 Antagonistes benzimidazolyles du recepteur du neuropeptide y Abandoned CA2242579A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9600344.7A GB9600344D0 (en) 1996-01-09 1996-01-09 Benzimidzolyl neuropeptide y receptor antagonists
GB9600344.7 1996-01-09
US2163696P 1996-07-12 1996-07-12
US60/021,636 1996-07-12

Publications (1)

Publication Number Publication Date
CA2242579A1 true CA2242579A1 (fr) 1997-07-17

Family

ID=26308442

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002242579A Abandoned CA2242579A1 (fr) 1996-01-09 1997-01-09 Antagonistes benzimidazolyles du recepteur du neuropeptide y

Country Status (5)

Country Link
EP (1) EP0871442A1 (fr)
JP (1) JP2000501107A (fr)
AU (1) AU2242197A (fr)
CA (1) CA2242579A1 (fr)
WO (1) WO1997025041A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040356A1 (fr) * 1997-03-12 1998-09-17 Banyu Pharmaceutical Co., Ltd. Medicaments contenant des derives d'aminopyridine comme ingredient actif
JP3711238B2 (ja) 1997-08-05 2005-11-02 ファイザー・プロダクツ・インク 神経ペプチドＹ受容体アンタゴニストとしての４−アミノピロ−ル（３，２−ｄ）ピリミジン
SE9703414D0 (sv) * 1997-09-23 1997-09-23 Astra Ab New compounds
DE19801648A1 (de) * 1998-01-17 1999-07-22 Bayer Ag alpha-Substituierte Lactone
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO2002046168A1 (fr) * 2000-12-07 2002-06-13 Astrazeneca Ab Composes therapeutiques de benzimidazole
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
BR0311593A (pt) 2002-06-05 2005-04-26 Hoffmann La Roche Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc
ZA200508439B (en) 2003-05-05 2007-03-28 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
EP1713780B1 (fr) 2004-02-05 2012-01-18 Probiodrug AG Nouveaux inhibiteurs de la glutaminyl-cyclase
JPWO2005080348A1 (ja) * 2004-02-19 2007-08-02 萬有製薬株式会社 新規スルホンアミド誘導体
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
EP2142514B1 (fr) 2007-04-18 2014-12-24 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
KR101660059B1 (ko) 2008-08-22 2016-09-26 박스알타 인코퍼레이티드 중합체 벤질 카르보네이트-유도체
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
WO2011131748A2 (fr) 2010-04-21 2011-10-27 Probiodrug Ag Nouveaux inhibiteurs
NZ608069A (en) 2010-10-06 2014-06-27 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
CA2831710A1 (fr) 2011-03-31 2012-10-04 Bayer Intellectual Property Gmbh Benzimidazoles substitues servant d'inhibiteurs de mps-1 kinase
CN103965113A (zh) * 2014-05-06 2014-08-06 四川大学 1-羟乙基-2-取代苯氧甲基苯并咪唑类化合物及其制备方法
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
JP6400869B1 (ja) * 2018-02-23 2018-10-03 日本曹達株式会社 ４，５−ジシアノ−２−（フルオロアルキル）イミダゾールの製造方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772703A (en) * 1986-01-27 1988-09-20 American Home Products Corporation 2-(phenoxymethyl)-quinazolines as antiallergic and antiinflammatory agents

Also Published As

Publication number Publication date
WO1997025041A1 (fr) 1997-07-17
JP2000501107A (ja) 2000-02-02
AU2242197A (en) 1997-08-01
EP0871442A1 (fr) 1998-10-21

Similar Documents

Publication Publication Date Title
CA2242579A1 (fr) Antagonistes benzimidazolyles du recepteur du neuropeptide y
US5574044A (en) Muscarine antagonists
US6340681B1 (en) 2-benzimidazolylamine compounds as ORL-1-receptor agonists
US6025372A (en) Somatostatin agonists
US6642228B1 (en) α1b-adrenergic receptor antagonists
AU717422B2 (en) Indolyl neuropeptide Y receptor antagonists
JP2000512296A (ja) セロトニン再取込み阻害
DE60119939T2 (de) Chinolinderivate als antibakterielle mittel
JP3315970B2 (ja) ニューロキニンアンタゴニストとしてのピペラジノ誘導体
JP4870163B2 (ja) Ｍｃｈ受容体アンタゴニストとしてのインダン誘導体
US20030191164A1 (en) Propane-1,3-dione derivatives
US7202245B2 (en) Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines
SK404491A3 (en) Tricyclic lactam compounds, pharmaceutical compositions comprising same and their use
CA3215564A1 (fr) Methodes et composes pour la restauration de la fonction du p53 mutant
US5691323A (en) Muscarine antagonists
CZ289479B6 (cs) Pouľití piperidinových derivátů pro výrobu farmaceutických prostředků, piperidinové deriváty a farmaceutický prostředek
AU2006275568A1 (en) Dipiperazinyl ketones and related analogues
WO2001027104A1 (fr) Derives d'imidazolidinone a substitution
JP2004504303A (ja) 選択的メラニン凝集ホルモン−１（ｍｃｈ１）受容体アンタゴニストおよびその使用
EP1373220B1 (fr) Benzimidazoles utiles dans le traitement de troubles sexuels
US6960589B2 (en) Benzimidazoles that are useful in treating sexual dysfunction
US6255494B1 (en) Benzimidzolyl neuropeptide Y receptor antagonists
US20040127504A1 (en) Benzimidazoles that are useful in treating sexual dysfunction
US7351828B2 (en) Benzimidazoles that are useful in treating sexual dysfunction
US6506756B2 (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists

Legal Events

Date Code Title Description
FZDE Dead